GlassScriptPhysician profile
Jared Thomas Alberts
NPI 1295172286
$1,384.20
in general payments reported to CMS, 2019-2025
19 companies · $376 in 2025
The $376 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $27.94 · 2020: $98.79 · 2021: $155 · 2022: $95.59 · 2023: $228 · 2024: $403 · 2025: $376.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $907 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $907.33 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $356.80 | 2020-2025 | Fasenra, Breztri, Tezspire |
| Astellas Pharma US INC | $142.22 | 2021 | |
| Mallinckrodt Hospital Products INC. | $118.17 | 2023 | Acthar |
| Grifols USA, LLC | $101.63 | 2020-2025 | Prolastin-C Liquid |
| Jazz Pharmaceuticals INC. | $91.00 | 2024-2025 | |
| Actelion Pharmaceuticals US, INC. | $72.99 | 2022-2024 | Opsumit, Uptravi |
| Merck Sharp & Dohme LLC | $72.23 | 2025 | Winrevair |
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.79 | 2019-2023 | Spiriva Respimat, Stiolto Respimat |
| Harmony Biosciences LLC | $60.95 | 2023-2025 | Wakix |
| Regeneron Healthcare Solutions, INC. | $58.50 | 2024-2025 | Dupixent |
| Glaxosmithkline, LLC. | $50.07 | 2019-2024 | Nucala |
| United Therapeutics Corporation | $48.79 | 2024-2025 | |
| Insmed, INC. | $44.93 | 2025 | Arikayce |
| Takeda Pharmaceuticals U.S.A., INC. | $24.36 | 2025 | Glassia |
| Amgen INC. | $21.26 | 2023 | Tezspire |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $15.57 | 2023 | Sunosi |
| Bayer Healthcare Pharmaceuticals INC. | $15.07 | 2022 | |
| Melinta Therapeutics, LLC | $13.98 | 2020 | |
| Electromed, INC. | $13.89 | 2025 | Smartvest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jared Alberts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.